GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults, after reporting data showing the shot is the first to work in the vulnerable age group for the major infectious disease.
葛蘭素史克(GSK)將申請(qǐng)批準(zhǔn)其針對(duì)老年人的呼吸道合胞病毒(RSV)疫苗。此前報(bào)告的數(shù)據(jù)顯示，該疫苗是首個(gè)對(duì)這一主要傳染病易感染人群發(fā)揮作用的疫苗。
您已閱讀9%（297字），剩余91%（3078字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專(zhuān)屬服務(wù)。